Agilent Technologies, Inc.

A · NYSE · Stock · Healthcare
$172.64
+0.61% today
Delayed price,

What Agilent Technologies does

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Key facts

Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$48.68B
P/E (ttm)
34.1
Forward P/E
25.6
Dividend yield
0.59%
Beta
1.21
Profit margin
19.5%
Employees
18,200
Headquarters
Santa Clara, CA, United States
Exchange
NYSE

Performance

1 Month
+10.3%
3 Months
+31.3%
6 Months
+41.7%
1 Year
+21.6%
5 Years
+14.4%
$108.3552-week range$177.05
Biggest setback — last 12 months
-28.2%
24 Nov 2025 → 23 Mar 2026
Fell from $153.50 to $110.24 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+56.7%
23 Mar 2026 → 21 Sept 2026
Ran from $110.24 to $172.79 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$158.29 (-8.3%)$172.64$188.30 (+9.1%)
3 Months$148.54 (-14.0%)$172.64$200.65 (+16.2%)
6 Months$139.57 (-19.2%)$172.64$213.55 (+23.7%)
12 Months$127.80 (-26.0%)$172.64$233.21 (+35.1%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 30.1%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 817 shares at $146.85 — Boehnlein Glenn S, Director · 2026-09-10
Sold 634 shares at $151.38 — Dolsten Mikael, Director · 2026-09-09
Sold 30 shares at $136.01 — KIRKWOOD JONAH PREVOST, Senior Vice President · 2026-06-29
Sold 418 shares at $137.40 — MCDONNELL PADRAIG, President and CEO · 2026-06-05
Sold 1,600 shares at $135.42 — Dolsten Mikael, Director · 2026-06-02
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.